trades at under 10x...6 months earnings, lol, if you take this quarter and likely next quarter, as well. just playing with the math. if you annualize this quarter's results, you get $7.80 Canadian. that's under 5x earnings without amdipharm. I think management previously said amdipharm will be accretive by 25%to 30% in 2016. just to be conservative, lets apply a 15% accretive multiple to $7.80 which gets us $8.97 a share in 2016. that's a $4.23 2016 p/e. maybe I'm missing something. looks pretty good to me. anyone know of another pharma stock that's traded at under 10x earnings, for a prolonged period of time, with a growing eps profile?